AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06413238
Drug: curcumin, saffron, Combination of saffron and curcumin and placebo
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
Trial: NCT04971356
Drug: Aspirin 100mg for 1-month (immediately after PCI)
RxNorm normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
Trial: NCT04971356
Drug: Ticagrelor 90mg for 6-month (immediately after PCI)
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
Trial: NCT04971356
Drug: Aspirin 100mg for 6-month (6-month post PCI)
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
Trial: NCT04971356
Drug: Aspirin 100mg for 12-month (immediately after PCI)
RxNorm normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
Trial: NCT00086034
Drug: Motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04971356
Drug: Ticagrelor 90mg for 12-month (immediately after PCI)
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
Trial: NCT06423170
Drug: Camrelizumab plus GEMOX
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses.
Trial: NCT04756050
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Trial: NCT04756050
Drug: Prilocaine HCl % 2 injectable solution
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Trial: NCT04677049
Drug: Niacin CRT
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A controlled release technology (CRT) tablet of Niacin
Trial: NCT04910503
Drug: Dexamethasone intravitreal implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Implant every 4 months if necessary
Trial: NCT04910503
Drug: Fluocinolone Acetonide Intravitreal Implant
RxNorm normalized name: Fluocinolone Acetonide Intravitreal Implant
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implantation
Trial: NCT00002313
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002313
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006195
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006195
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06614985
Drug: Telitacicept
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 160 mg is administered once a week.
Trial: NCT06614985
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.
Trial: NCT06614348
Drug: Sodium hyaluronate eye drops
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
Trial: NCT06518005
Drug: Imlifidase
RxNorm normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
Trial: NCT05526911
Drug: TBAJ-876
RxNorm normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed
Trial: NCT05526911
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
Trial: NCT05526911
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
Trial: NCT05025449
Drug: Bubble-Enhanced FAST (BEFAST)
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
Trial: NCT04872595
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (5mg/kg/day x 2 day) Day -5 to -4
Trial: NCT04872595
Drug: GCSF
RxNorm normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day +7
Trial: NCT04872595
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
Trial: NCT04872595
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (70mg/m2/day x 2 days) Day -6 to -5
Trial: NCT04872595
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (25mg/m2/day x 5 days) Day -6 to -2
Trial: NCT05345938
Drug: Mitoxantrone Hydrochloride Liposome
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
Trial: NCT01131247
Drug: ofatumumab + bendamustine
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
Trial: NCT05604131
Drug: Deferiprone Tablets
RxNorm normalized name: Deferiprone Tablets
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
Trial: NCT04775225
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: denervation of the obturator and femoral genicular branches by Lidocaine 2 %
Trial: NCT04843943
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab: 200mg IV Q3W D1
Trial: NCT04843943
Drug: Bevacizumab Biosimilar
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
Trial: NCT06337110
Drug: Lu AF28996
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution containing radiolabelled \[14C\]-Lu AF28996.
Trial: NCT06444009
Drug: Ivonescimab combined with TP
RxNorm normalized name: miconazole
DrugBank: Ivonescimab (DB18931)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Trial: NCT06444009
Drug: Cadonilimab combined with TP
RxNorm normalized name: miconazole
DrugBank: Cadonilimab (DB16680)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Trial: NCT06444009
Drug: Penpulimab combined with TP
RxNorm normalized name: miconazole
DrugBank: Penpulimab (DB16747)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Trial: NCT05114109
Drug: Isatuximab Injection
RxNorm normalized name: isatuximab Injection
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
Trial: NCT05285540
Drug: DT-216
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DT-216 will be administered by intravenous (IV) injection
Trial: NCT04990791
Drug: Aspirin 75mg
RxNorm normalized name: ASPIRIN 75MG CHEW TAB
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 75mg OD for 14 days
Trial: NCT04990791
Drug: Aspirin 20mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 20mg BD for 14 days
Trial: NCT04990791
Drug: Rivaroxaban 2.5 mg
RxNorm normalized name: rivaroxaban 2.5 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 2.5mg BD
Trial: NCT04555044
Drug: Clinolipid
RxNorm normalized name: Clinolipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid injectable emulsion, USP 20%
Trial: NCT04555044
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
Trial: NCT05702398
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 μg retinyl palmitate twice a day for 6 months
Trial: NCT06430645
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
Trial: NCT06430645
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
Trial: NCT06430645
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
Trial: NCT06245109
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg, oral
Trial: NCT00691951
Drug: budesonide and budesonide/formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05478083
Drug: Leuprorelin
RxNorm normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
Trial: NCT05839756
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
Trial: NCT04742036
Drug: Capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
Trial: NCT04742036
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression.
Trial: NCT05274269
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT05450029
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
Trial: NCT05252624
Drug: Henagliflozin 5Mg Tab
RxNorm normalized name: bexagliflozin Oral Tablet
DrugBank: Henagliflozin (DB11939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral tablet
Trial: NCT05525650
Drug: House Dust Mite Extract, Dermatophagoides Farinae
RxNorm normalized name: House dust mite extract, dermatophagoides farinae
DrugBank: Dermatophagoides farinae (DB10400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E.
Trial: NCT05506930
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
Trial: NCT05506930
Drug: Quadratus lumborum block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
Trial: NCT03660917
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
Trial: NCT05037851
Drug: Opelconazole
RxNorm normalized name: Opelconazole
DrugBank: Opelconazole (DB18251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer suspension
Trial: NCT04908982
Drug: Aspirin 81mg
RxNorm normalized name: ASPIRIN 81MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
Trial: NCT06508671
Drug: DL-3-n-butylphthalide
RxNorm normalized name: DL-3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take butylphthalide soft capsules orally
Trial: NCT05651672
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 13.5mg, po, 2 weeks on/1 week off, Q3W
Trial: NCT06525584
Drug: Ketamine Hcl 50Mg/Ml Inj
RxNorm normalized name: KETAMINE HCL 50MG/ML INJ
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
Trial: NCT06525584
Drug: Ketamine Hcl 50Mg/Ml Inj
RxNorm normalized name: KETAMINE HCL 50MG/ML INJ
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
Trial: NCT00001094
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001094
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001094
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001094
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06118762
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.